RIVASMINA
|
Lafedar
|
rivastigmina |
Trat.enf.Alzheimer |
1.5 mg caps.x 14 | $12114.49 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $3714.34 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $5324.30 AF $6790.19 |
|
|
|
|
1.5 mg caps.x 28 | $19382.75 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $5942.79 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $13393.58 AF $5989.17 |
|
|
|
|
1.5 mg caps.x 56 | $26464.54 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $8114.19 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $38584.67 AF $0.00 |
|
|
|
|
3 mg caps.x 14 | $12114.49 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $3714.34 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $5324.30 AF $6790.19 |
|
|
|
|
3 mg caps.x 28 | $19382.75 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $5942.79 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $13399.97 AF $5982.78 |
|
|
|
|
3 mg caps.x 56 | $26464.54 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $8114.19 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $38584.67 AF $0.00 |
|
|
|
|
4.5 mg caps.x 14 | $12114.49 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $3714.34 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $5324.30 AF $6790.19 |
|
|
|
|
4.5 mg caps.x 28 | $19382.75 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $5942.79 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $13488.21 AF $5894.54 |
|
|
|
|
4.5 mg caps.x 56 | $26464.54 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $8114.19 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $11631.13 AF $14833.41 |
|
|
|
|
6 mg caps.x 14 | $12114.49 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $3714.34 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $5324.30 AF $6790.19 |
|
|
|
|
6 mg caps.x 28 | $19382.75 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $5942.79 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $13842.79 AF $5539.96 |
|
|
|
|
6 mg caps.x 56 | $26464.54 | (21/03/24) |
SIFAR |
Producto Reconocido |
|
PAMI |
|
AF $8114.19 |
|
|
IOMA |
Cobertura Monto Fijo |
OS $11631.13 AF $14833.41 |
|
|
|
|
|